Abstract
Somatostatin (SS) is an inhibitory regulator of secretory and proliferative responses that activates a group of receptors in the plasma membrane termed SSR1–5. SSR2 is one of the most abundant SSR, which also is expressed in high numbers in many neuroendocrine tumor types. Here, we describe a study of the presence and intracellular localization of the spliced variant SSR2(a) and its endogenous ligand SS in the cultured human neuroblastoma (NB) cell line, SH-SY5Y, by immunohistochemistry and confocal laser scanning. The integral neuronal synaptic vesicle membrane proteins synaptophysin (p38) and SV2 were studied, as well as the IR of catecholaminergic and cholinergic markers. RA treatment was used as an inducer of neuronal-like differentiation in our SH-SY5Y cell line. After the treatment, the presence of catecholaminergic markers (including NPY) decreased while the cholinergic markers (including VIP) increased. p38 and SV2 as well as VIP were shifted into the rather long neuritic processes, indicating efficient intracellular transport. The SSR2(a) protein was significantly increased by RA treatment, but only minor increases in mRNA for this receptor protein could be seen. No subcellular co-localization between p38/SV2 and the cytoplasmic granular receptor material was demonstrated. The SSR2(a) receptor ligand SS was found to be present not only in the cytoplasm but also in the nucleus, and more strongly so after RA treatment. The possible reason for this may be that this peptide, like other small peptides, may serve as transcription factor, or cofactor.
Similar content being viewed by others
REFERENCES
Reubi, J. C., Schaer, J. C., Markwalder, R., Waser, B., Horisberger, U., and Laissue, J. 1997. Distribution of somatostatin receptors in normal and neoplastic human tissues: Recent advances and potential relevance. Yale J. Biol. Med. 70:471–479.
Patel, Y. C. 1999. Somatostatin and its receptor family. Front Neuroendocrinol. 20:157–198.
Raulf, F., Perez, J., Hoyer, D., and Bruns, C. 1994. Differential expression of five somatostatin receptor subtypes, SSTR1-5, in the CNS and peripheral tissue. Digestion 55:46–53.
Epelbaum, J., Bertherat, J., Prevost, G., Kordon, C., Meyerhof, W., Wulfsen, I., Richter, D., and Plouin, P. F. 1995. Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal, and malignant pheochromocytomas. J. Clin. Endocrinol. Metab. 80:1837–1844.
Vanetti, M., Kouba, M., Wang, X., Vogt, G., and Hollt, V. 1992. Cloning and expression of a novel mouse somatostatin receptor (SSTR2B). FEBS Lett. 311:290–294.
Patel, Y. C., Greenwood, M., Kent, G., Panetta, R., and Srikant, C. B. 1993. Multiple gene transcripts of the somatostatin receptor SSTR2: Tissue selective distribution and cAMP regulation. Biochem. Biophys. Res. Com. 192:288–294.
Biedler, J. L., Roffler-Tarlov, S., Schachner, M., and Freedman, L. S. 1978. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res. 38:3751–3757.
Biedler, J. L., Helson, L., and Spengler, B. A. 1973. Morphology and growth, tumorgenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res. 33:2643–2652.
Goodall, A. R., Danks, K., Walker, J. H., Ball, S. G., and Vaughan, P. F. 1997. Occurrence of two types of secretory vesicles in the human neuroblastoma SH-SY5Y. J. Neurochem. 68:1542–1552.
Ciccarone, V., Spengler, B. A., Meyers, M. B., Biedler, J. L., and Ross, R. A. 1989. Phenotypic diversification in human neuroblastoma cells: Expression of distinct neural crest lineage. Cancer Res. 49:219–225.
Spinelli, W. 1982. Effects of phorbol ester tumor promoters and nerve growth factor on neurite outgrowth in cultured human neuroblastoma cells. Cancer Res. 42:5067–5073.
Påhlman, S., Ruusala, A. I., Abrahamsson, L., Mattsson, M. E., and Esscher, T. 1984. Retinoic acid-induced differentiation of cultured human neuroblastoma cells: A comparison with phorbolester-induced differentiation. Cell Differ. 14:135–144.
Påhlman, S., Mamaeva, S., Meyerson, G., Mattsson, M. E., Bjelfman, C., Ortoft, E., and Hammerling, U. 1990. Human neuroblastoma cells in culture: A model for neuronal cell differentiation and function. Acta Physiol. Scand. (Suppl.) 592:25–37.
Goldstein, M., Fuxe, K., and Hokfelt, T. 1972. Characterization and tissue localization of catecholamine synthesizing enzymes. Pharmacol. Rev. 24:293–309.
Peter, D., Liu, Y., Sternini, C., de Giorgio, R., Brecha, N., and Edwards, R. H. 1995. Differential expression of two vesicular monoamine transporters. J. Neurosci. 15:6179–6188.
Buckley, K. and Kelly, R. B. 1985. Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells. J. Cell Biol. 100:1284–1294.
Jahn, R., Schiebler, W., Ouimet, C., and Greengard, P. 1985. A 38,000-dalton membrane protein (p38) present in synaptic vesicles. Proc. Natl. Acad. Sci. USA 82:4137–4141.
Schindler, M., Sellers, L. A., Humphrey, P. P., and Emson, P. C. 1997. Immunohistochemical localization of the somatostatin SST2(A) receptor in the rat brain and spinal cord. Neuroscience 76:225–240.
Chomczynski, P. and Sacchi, N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156–159.
Forssell-Aronsson, E. B., Nilsson, O., Bejegard, S. A., Kolby, L., Bernhardt, P., Molne, J., Hashemi, S. H., Wangberg, B., Tisell, L. E., and Ahlman, H. 2000. 111In-DTPA-D-Phel-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J. Nucl. Med. 41:636–642.
Agoston, D. V., Colburn, S., Krajniak, K. G., and Waschek, J. A. 1992. Distinct regulation of vasoactive intestinal peptide (VIP) expression at mRNA and peptide levels in human neuroblastoma cells. Neurosci. Lett. 139:213–216.
Pence, J. C. and Shorter, N. A. 1992. Autoregulation of neuroblastoma growth by vasoactive intestinal peptide. J. Pediatr. Surg. 27:935–943.
LoPresti, P., Poluha, W., Poluha, D. K., Drinkwater, E., and Ross, A. H. 1992. Neuronal differentiation triggered by blocking cell proliferation. Cell Growth. Differ. 3:627–635.
Zadina, J. E., Chang, S. L., Ge, L. J., and Kastin, A. J. 1993. Mu opiate receptor down-regulation by morphine and up-regulation by naloxone in SH-SY5Y human neuroblastoma cells. J. Phar-macol. Exp. Ther. 265:254–262.
Hornick, C. A., Anthony, C. T., Hughey, S., Gebhardt, B. M., Espenan, G. D., and Woltering, E. A. 2000. Progressive nuclear translocation of somatostatin analogs. J. Nucl. Med. 41:1256–1263.
Raper, S. E., Burwen, S. J., Barker, M. E., and Jones, A. L. 1987. Translocation of epidermal growth factor to the hepatocyte nucleus during rat liver regeneration. Gastroenterology 2:1243–1250
Björklund, S. and Kim, Y. J. 1996. Mediator of transcriptional regulation. Trends Biochem. Sci. 21:335–337.
Henderson, J. E. 1997. Nuclear targeting of secretory proteins. Mol. Cell Endocrinol. 129:1–5.
Mitchell, P. J. and Tjian, R. 1989. Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins. Science 245:371–378.
Nilsson, C. L., Murphy, C. M., and Ekman, R. 1997. Isolation and characterization of proteins from human lymphocyte nuclei using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and post-source decay analysis. Rapid Commun. Mass. Spectrom 11:610–612.
Blomqvist, M., Bergquist, J., Westman, A., Hakansson, K., Hakansson, P., Fredman, P., and Ekman, R. 1999. Identification of defensins in human lymphocyte nuclei. Eur. J. Biochem. 263:312–318.
Ekman, R., Gobom, J., Persson, R., Mecocci, P., and Nilsson, C. L. 2001. Arginine vasopressin in the cytoplasm and nuclear fraction of lymphocytes from healthy donors and patients with depression or schizophrenia. Peptides 22:67–72.
Bergquist, J. and Ekman, R. 2001. Future aspects of psychoneuroimmunology: Lymphocytes peptides reflecting psychiatriatic disorders by mass spectrometry. Arch Phys. Biochem. 109:369–371.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hashemi, S.H., Li, JY., Ahlman, H. et al. SSR2(a) Receptor Expression and Adrenergic/Cholinergic Characteristics in Differentiated SH-SY5Y Cells. Neurochem Res 28, 449–460 (2003). https://doi.org/10.1023/A:1022848718109
Issue Date:
DOI: https://doi.org/10.1023/A:1022848718109